Clinical trial
A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants
NCT06772870 is registered in ClinicalTrials.gov with Design Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants
- Lead sponsor
- Design Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- February 28, 2025
- Completion date
- December 31, 2025
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.